EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Objective: to study the clinical efficacy, immunogenicity, and safety of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis (RA). Subjects and methods. The investigation enrolled 70 patients (55 women and 15 men) aged 23–70 years, including 40 patients with RA and 30 people witho...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-05-01
|
| Series: | Klinicist |
| Subjects: | |
| Online Access: | https://klinitsist.abvpress.ru/Klin/article/view/184 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240144355262464 |
|---|---|
| author | M. S. Naumtseva B. S. Belov G. M. Tarasova D. E. Karateev E. L. Luchikhina Yu. V. Muravyev E. N. Aleksandrova A. A. Novikov |
| author_facet | M. S. Naumtseva B. S. Belov G. M. Tarasova D. E. Karateev E. L. Luchikhina Yu. V. Muravyev E. N. Aleksandrova A. A. Novikov |
| author_sort | M. S. Naumtseva |
| collection | DOAJ |
| description | Objective: to study the clinical efficacy, immunogenicity, and safety of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis (RA). Subjects and methods. The investigation enrolled 70 patients (55 women and 15 men) aged 23–70 years, including 40 patients with RA and 30 people without systemic inflammatory rheumatic diseases (a control group) who had a recent history of 2 and more cases of lower respiratory tract infections (bronchitis, pneumonia). When included, all the patients received anti-inflammatory therapy with methotrexate (MT) (n = 24), leflunomide (LEF) (n = 6), or MT + tumor necrosis factor-α (TNF-α) inhibitors (n = 10). A single 0.5-ml dose of the 23-valent pneumococcal vaccine Pneumo-23 (Sanofi Pasteur) was administered subcutaneously or intramuscularly during continuous MT or LEF therapy for the underlying disease or 3–4 weeks before the use of a TNF-α inhibitor. During control visits (1 and 3 months and 1 year after administration of the vaccine), the patients underwent physical examination and routine clinical and laboratory studies. Results. No clinical and radiological symptoms of pneumonia were recorded in any case during a 12-month follow-up. The RA and control groups showed a more than 2-fold increase in anti-pneumococcal antibody levels 1 year after vaccination. The vaccine was well tolerated by 50 patients. Sixteen patients were observed to have pain, cutaneous swelling and hyperemia and 4 had subfebrility. There were neither episodes of RA exacerbation nor new autoimmune disorders during the follow-up. Conclusion. The findings suggest that 23-valent pneumococcal vaccine shows a good clinical efficacy, adequate immunogenicity, and good tolerability in the patients with RA. |
| format | Article |
| id | doaj-art-5128fe70757d4ef38e5b4733871fa564 |
| institution | Kabale University |
| issn | 1818-8338 |
| language | Russian |
| publishDate | 2015-05-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Klinicist |
| spelling | doaj-art-5128fe70757d4ef38e5b4733871fa5642025-08-20T04:00:43ZrusABV-pressKlinicist1818-83382015-05-0191606310.17650/1818-8338-2015-1-60-63189EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITISM. S. Naumtseva0B. S. Belov1G. M. Tarasova2D. E. Karateev3E. L. Luchikhina4Yu. V. Muravyev5E. N. Aleksandrova6A. A. Novikov7V.A. Nasonova Research Institute of Rheumatology; 34А Kashirskoe Shosse, Moscow, 115522, RussiaV.A. Nasonova Research Institute of Rheumatology; 34А Kashirskoe Shosse, Moscow, 115522, RussiaV.A. Nasonova Research Institute of Rheumatology; 34А Kashirskoe Shosse, Moscow, 115522, RussiaV.A. Nasonova Research Institute of Rheumatology; 34А Kashirskoe Shosse, Moscow, 115522, RussiaV.A. Nasonova Research Institute of Rheumatology; 34А Kashirskoe Shosse, Moscow, 115522, RussiaV.A. Nasonova Research Institute of Rheumatology; 34А Kashirskoe Shosse, Moscow, 115522, RussiaV.A. Nasonova Research Institute of Rheumatology; 34А Kashirskoe Shosse, Moscow, 115522, RussiaV.A. Nasonova Research Institute of Rheumatology; 34А Kashirskoe Shosse, Moscow, 115522, RussiaObjective: to study the clinical efficacy, immunogenicity, and safety of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis (RA). Subjects and methods. The investigation enrolled 70 patients (55 women and 15 men) aged 23–70 years, including 40 patients with RA and 30 people without systemic inflammatory rheumatic diseases (a control group) who had a recent history of 2 and more cases of lower respiratory tract infections (bronchitis, pneumonia). When included, all the patients received anti-inflammatory therapy with methotrexate (MT) (n = 24), leflunomide (LEF) (n = 6), or MT + tumor necrosis factor-α (TNF-α) inhibitors (n = 10). A single 0.5-ml dose of the 23-valent pneumococcal vaccine Pneumo-23 (Sanofi Pasteur) was administered subcutaneously or intramuscularly during continuous MT or LEF therapy for the underlying disease or 3–4 weeks before the use of a TNF-α inhibitor. During control visits (1 and 3 months and 1 year after administration of the vaccine), the patients underwent physical examination and routine clinical and laboratory studies. Results. No clinical and radiological symptoms of pneumonia were recorded in any case during a 12-month follow-up. The RA and control groups showed a more than 2-fold increase in anti-pneumococcal antibody levels 1 year after vaccination. The vaccine was well tolerated by 50 patients. Sixteen patients were observed to have pain, cutaneous swelling and hyperemia and 4 had subfebrility. There were neither episodes of RA exacerbation nor new autoimmune disorders during the follow-up. Conclusion. The findings suggest that 23-valent pneumococcal vaccine shows a good clinical efficacy, adequate immunogenicity, and good tolerability in the patients with RA.https://klinitsist.abvpress.ru/Klin/article/view/184rheumatoid arthritisautoimmune diseasescomorbid infectionscomorbiditypneumoniabronchitispneumococcal vaccinevaccinationimmunogenicityefficacytolerability |
| spellingShingle | M. S. Naumtseva B. S. Belov G. M. Tarasova D. E. Karateev E. L. Luchikhina Yu. V. Muravyev E. N. Aleksandrova A. A. Novikov EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS Klinicist rheumatoid arthritis autoimmune diseases comorbid infections comorbidity pneumonia bronchitis pneumococcal vaccine vaccination immunogenicity efficacy tolerability |
| title | EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_full | EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_fullStr | EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_full_unstemmed | EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_short | EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_sort | efficacy and safety of 23 valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis |
| topic | rheumatoid arthritis autoimmune diseases comorbid infections comorbidity pneumonia bronchitis pneumococcal vaccine vaccination immunogenicity efficacy tolerability |
| url | https://klinitsist.abvpress.ru/Klin/article/view/184 |
| work_keys_str_mv | AT msnaumtseva efficacyandsafetyof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT bsbelov efficacyandsafetyof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT gmtarasova efficacyandsafetyof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT dekarateev efficacyandsafetyof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT elluchikhina efficacyandsafetyof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT yuvmuravyev efficacyandsafetyof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT enaleksandrova efficacyandsafetyof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT aanovikov efficacyandsafetyof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis |